http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2659423-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-94 |
| filingDate | 2007-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1ba40d9c722b782ad4c7c93193ce14f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c595895e8acf440dfe1a98e44f54bee4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66b89f79ffedcbb702c74657a47364d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd096e713c06839cf9d64da9635c54a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c2d1a13f5c22c7ad8080336b3333ab3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_358ba864b3f5ee7c1e94bb8d98315aab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9855b23e38cc3efc7d29a66a3d549714 |
| publicationDate | 2008-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2659423-A1 |
| titleOfInvention | The use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents |
| abstract | The present invention relates to the diagnosis of the risk of experiencing a cardiovascular complication in the context of treatment with erythropoiesis stimulating agents (ESAs) such as erythropoetin and derivatives thereof, particularly in the context of anemia. More particularly, the invention provides a method for diagnosing the risk of a patient of experiencing a cardiovascular complication as a consequence of future medication with an erythropoiesis stimulating agent (ESA), comprising the steps of (a) measuring the level of a BNP -type peptide in a sample of the patient, (b) diagnosing said risk by comparing the measured level of the BNP -type peptide to at least one reference level. The BNP -type peptide may for example be brain natriuretic peptide (BNP) or the N-terminal fragment of BNP, NT-proBNP. The cardiovascular complication may include complications such as stroke, transient cerebral ischemic attack, acute coronary syndrome, myocardial infarction, congestive heart failure etc.. Notably, the present invention also relates to dosages of ESA medication which do not cause hyperviscosity. |
| priorityDate | 2006-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 224.